Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics source : Ir.akerotx.com save search
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
Published: 2023-06-05 (Crawled : 11:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -1.84%
H: 17.9%
C: 13.41%
disease therapy study
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Published: 2023-06-01 (Crawled : 20:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.73%
H: 3.37%
C: 2.82%
efruxifermin expansion trial therapeutics results
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
Published: 2023-03-29 (Crawled : 20:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -6.62%
fda positive efruxifermin meeting program therapeutics nash
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Published: 2023-03-17 (Crawled : 11:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.58%
H: 1.98%
C: 0.65%
year therapeutics financial results
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
Published: 2023-01-10 (Crawled : 13:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.39%
H: 2.19%
C: 0.25%
commercial therapeutics
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-04 (Crawled : 13:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.2%
H: 1.23%
C: -10.28%
conference therapeutics
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
Published: 2022-12-21 (Crawled : 21:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.02%
H: 6.34%
C: 6.12%
expected therapeutics study phase 2b
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Published: 2022-12-08 (Crawled : 12:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.93%
H: 5.17%
C: 2.47%
fda designation granted therapy nash efruxifermin
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
Published: 2022-11-10 (Crawled : 22:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.35%
H: 5.4%
C: 2.55%
therapeutics
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
Published: 2022-11-07 (Crawled : 13:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 2.39%
H: 2.39%
C: -3.12%
meeting liver therapeutics today
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-04 (Crawled : 11:00) - ir.akerotx.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 1.83%
H: 0.7%
C: -0.35%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.46%
H: 4.12%
C: -5.62%
therapeutics financial update results
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
Published: 2022-10-11 (Crawled : 21:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 1.42%
H: 2.33%
C: 1.4%
conference therapeutics nash
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Published: 2022-09-19 (Crawled : 20:00) - ir.akerotx.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.7%
H: 0.4%
C: -1.03%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.63%
H: 3.32%
C: -1.9%
offering therapeutics
Akero Therapeutics Announces Proposed Public Offering of Common Stock
Published: 2022-09-13 (Crawled : 20:00) - ir.akerotx.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.56%
H: 0.65%
C: -0.41%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.0%
H: 1.2%
C: -4.65%
offering therapeutics
In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
Published: 2022-09-13 (Crawled : 10:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 128.52%
H: 6.21%
C: 3.6%
phase 2b
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH
Published: 2022-09-08 (Crawled : 20:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -1.37%
H: 0.08%
C: -9.92%
trial therapeutics results nash efruxifermin phase 2b
Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment
Published: 2022-08-24 (Crawled : 12:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.25%
H: 10.47%
C: 9.11%
treatment fibrosis nash study efruxifermin
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-04 (Crawled : 21:00) - ir.akerotx.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.44%
H: 0.66%
C: -0.75%
HTGC 4 | $18.96 0.58% 0.0% 620K
|
Finance
|
| O: 0.13%
H: 2.69%
C: 2.69%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 1.33%
H: 6.94%
C: 6.33%
therapeutics update results
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis
Published: 2022-06-27 (Crawled : 11:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.0%
H: 0.87%
C: -2.89%
fibrosis liver therapeutics international nash efruxifermin
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
Published: 2022-06-16 (Crawled : 11:00) - ir.akerotx.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
HTGC 4 | $18.96 0.58% 0.0% 620K
|
Finance
|
| O: -2.88%
H: 1.33%
C: 0.08%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 17.77%
H: 14.88%
C: 10.2%
therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.